drugset / Trial / NCT02944357

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

NCT02944357

NaSingle-groupOpen-labelTreatment

Summary

This pilot clinical trial studies how well gemcitabine hydrochloride, cisplatin, and AGS-003-BLD work in treating patients with bladder cancer that has spread to the muscle and who are undergoing surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vaccines made from a person's tumor cells may help the body build an effective immune response to kill tumor cells. Giving gemcitabine hydrochloride, cisplatin, and AGS-003-BLD before surgery may make the tumor smaller and reduce the amount of tissue that needs to be removed by surgery.

Timeline

Start
2016-11
Primary completion
2017-09-05
Completion
2017-09-05

Drugs

EvaluationDrugModalityDoseRoute
Subject AGS-003-BLD Unknown Intravitreal
Subject Cisplatin Other / unclassified Intravenous
Subject Gemcitabine Small molecule Intravenous